Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 3Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Plasma Cell 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 23Cyclophosphamide 21Prednisone 16Doxorubicin 14Magnetic Resonance Spectroscopy 13Vincristine 11Specimen Handling 11Lenalidomide 10ibrutinib 8Biopsy 8obinutuzumab 7polatuzumab vedotin 6glofitamab 6Gemcitabine 6Oxaliplatin 5venetoclax 4prednylidene 4pembrolizumab 4fludarabine 4deltacortene 4Prednisolone 4Etoposide 4Dexamethasone 4Cyclosporine 4CT-P10 4fludarabine phosphate 3Whole-Body Irradiation 3R-CHOP protocol 3Nivolumab 3Mycophenolic Acid 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Hyaluronoglucosaminidase × 30 days × Clear all
NCT04799275 2026-05-13

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
422 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡